A Randomized Phase II Trial of Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine and Cisplatin Compared to Gemcitabine and Cisplatin in Treatment-naïve Patients With Cholangio- and Gallbladder Carcinoma (IMMUCHEC)
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Cisplatin; Gemcitabine
- Indications Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- Acronyms IMMUCHEC
- 12 Sep 2019 Planned End Date changed from 1 Jul 2021 to 1 Sep 2021.
- 12 Sep 2019 Planned primary completion date changed from 1 Jul 2020 to 1 Sep 2021.
- 19 Jun 2018 Status changed from not yet recruiting to recruiting.